A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.

Dave SinghMaxim BogusValentyn MoskalenkoRobert LordEdmund J MoranGlenn D CraterDavid L BourdetNathan D PfeiferJacky WooElad KaufmanDavid A LombardiEmily Y WengTuan NguyenAshley WoodcockBrett HaumannRajeev Saggar

Published in: The European respiratory journal (2021)

Keyphrases

coronavirus disease
sars cov
cystic fibrosis
early onset
pulmonary artery
coronary artery
pulmonary arterial hypertension
drug induced